IP Library Granted Patent US 8,894,997
Granted Patent B2
US 8,894,997 · App. 13/318,020 · Granted Nov 25, 2014

Monoclonal antibodies to influenza H1N1 virus uses thereof

Inventors: James E. Crowe (Nashville, TN); Christopher F. Basler (Hastings on Hudson, NY)
Assignees: Vanderbilt University; Icahn School of Medicine at Mount Sinai
C07K16/1018C07K2316/96G01N33/56983C07K2317/21A61K2039/505C07K2317/56G01N2333/11C07K2317/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,894,997
App. No.
13/318,020
Granted
Nov 25, 2014
Kind
B2
Abstract

The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of influenza virus infections. In particular, these antibodies may neutralize or limit the replication of H1N1 influenza virus. Also disclosed are improved methods for producing such monoclonal antibodies.

Claims (6)

1. An expression vector comprising a nucleic acid molecule encoding a heavy chain variable region comprising the sequence of SEQ ID NO: 7.

2. An expression vector comprising a nucleic acid molecule encoding a light chain variable region comprising the sequence of SEQ ID NO: 8.

3. The expression vector of claim 1 , wherein said expression vector comprises a promoter operatively linked to said nucleic acid molecule.

4. The expression vector of claim 2 , wherein said expression vector comprises a promoter operatively linked to said nucleic acid molecule.

5. An isolated antibody or antigen binding fragment thereof comprising the heavy chain of SEQ ID NO: 7 and the light chain of SEQ ID NO: 8, wherein the antibody or antigen binding fragment thereof is conjugated to a heterologous agent selected from the group consisting of: diagnostic agent, therapeutic agent, and an effector molecule.

6. The isolated antibody or antigen binding fragment thereof of claim 5 , dispersed in a pharmaceutically acceptable carrier.

Assignments (3)
CONFIRMATORY LICENSE Recorded Dec 14, 2016
From: VANDERBILT UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040732/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2014
From: CROWE, JAMES E., JR; KRAUSE, JENS C.
To: VANDERBILT UNIVERSITY
Reel/Frame 032673/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2014
From: BASLER, CHRISTOPHER F.
To: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Reel/Frame 032053/0757 →
Continuity (2)
Provisional Application 61174415 · Apr 30, 2009
Related Publication 20120100142A1 · Apr 26, 2012